Drug Profile


Alternative Names: S-Benatoprazole; S-Tenatoprazole sodium; sTU-199; STU-Na; TU-199

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Abbott Japan; Mitsubishi Pharma Corporation; Negma SAS; Steba Laboratories
  • Class Antiulcers; Gastric antisecretories; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Gastro-oesophageal reflux
  • Discontinued Peptic ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in European Union (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in Canada (PO)
  • 22 May 2008 Pharmacodynamics data from four studies in healthy volunteers presented at the Digestive Disease Week 2008 (DDW-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top